Futibatinib — Drug Intelligence | 9 EU Trials

Filter these 9 trials by condition, phase, country and more.

9 Registered trials

6 Recruiting

3 Completed trials

6 Sponsors

10 Countries

Phase III

Phase II/III

Phase II

Phase I/II

Phase III: 2 Phase II/III: 1 Phase II: 5 Phase I/II: 1

Oversight events:

1 urgent safety measure across 1 trial

Indications tested

9 total

An Open-label, Rollover Study of Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib Study Recruiting

2024-512217-40-00 Phase II/III 4 countries Taiho Oncology Inc.
FUTURE Recruiting

2024-517573-24-00 Phase II 1 country Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
Personalized medicine for advanced biliary cancer patients Recruiting

2023-508100-38-00 Phase III 2 countries Unicancer
FOENIX-CCA4 Recruiting

2023-503665-39-00 Phase II 4 countries Taiho Oncology Inc.
A modular multi-Basket trial to improve personalized medicine in cancer patients Recruiting

2024-514238-19-00 Phase II 6 countries Vall D Hebron Institute Of Oncology
AcSé-ESMART: European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors Recruiting

2024-514791-40-00 Phase I/II 5 countries Institut Gustave Roussy
Phase 2 Futibatinib in Combination with PD-1 Antibody-based Standard of Care in Solid Tumors Ended

2023-507516-12-00 Phase II 3 countries Taiho Oncology Inc.
A Phase 2 Study Evaluating Futibatinib (TAS-120) Plus Pembrolizumab in the Treatment of Advanced or Metastatic bladder, urethra or pelvis ca… Ended

2024-513760-26-00 Phase II 1 country Taiho Oncology Inc.
MULTISARC : MOLECULAR PROFILING OF ADVANCED SOFT-TISSUE SARCOMAS. A phase III study Ended

2024-514873-22-00 Phase III 1 country Institut National De La Sante Et De La Recherche Medicale

Showing 1–9 of 9 trials